At the completion of this activity, the participant will be able to:
1. Recall the patient population studied in major atrial fibrillation and DVT/PE DOAC trials
2. Discuss subgroup analyses and available cohort studies regarding DOAC use in patients with advanced kidney disease
3. Review available subgroup and post-hoc analyses regarding DOAC use in patients with elevated BMI
4. Identify the most appropriate DOAC agents for use in the CKD and obese patient population in practice